Triple threat: three new targeted drugs join forces with immunotherapy to attack Hard-to-Treat breast cancer
NCT ID NCT06433609
First seen Jul 14, 2026 · Last updated Jul 15, 2026 · Updated 1 time
Summary
This phase II trial tests whether combining three experimental antibody-drug conjugates (SHR-A1811, SHR-A1921, and SHR-A2102) with the immunotherapy drug adebrelimab can shrink tumors in people with HER2-negative advanced breast cancer. Participants must have already tried at least one prior systemic therapy. The study measures how many patients respond to treatment and how long the benefit lasts.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
- Active substance
- three experimental antibody-drug conjugates (SHR-A1811, SHR-A1921, SHR-A2102) combined with an immunotherapy drug called adebrelimab
- What this could lead to
- If successful, this combination could offer a new treatment option for people with HER2-negative advanced breast cancer who have run out of standard therapies.
- What could go wrong
- This is an early-phase trial with a small number of participants, so the benefits may not be confirmed in larger studies. The combination may cause significant side effects.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for ADVANCED BREAST CANCER are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Beijing GoBroad Hospital
RECRUITINGBeijing, Beijing Municipality, 102200, China
Contact Phone: •••-•••-•••• Email: •••••@•••••
Contact
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Blood tests could reveal hidden resistance in breast cancer
- New drug sequence aims to outsmart advanced breast cancer
- Could a pill replace an IV for advanced breast cancer treatment?
- Blood test timing could unlock secrets of advanced breast cancer
- Oral chemotherapy pill tested for advanced breast cancer
- New oral drug aims to tackle Hormone-Driven cancers